WO2014090261A1 - Mixture of fucosylate lactoses - Google Patents

Mixture of fucosylate lactoses Download PDF

Info

Publication number
WO2014090261A1
WO2014090261A1 PCT/DK2013/050431 DK2013050431W WO2014090261A1 WO 2014090261 A1 WO2014090261 A1 WO 2014090261A1 DK 2013050431 W DK2013050431 W DK 2013050431W WO 2014090261 A1 WO2014090261 A1 WO 2014090261A1
Authority
WO
WIPO (PCT)
Prior art keywords
dfl
mixture
fucosidase
acid
hydrolysis
Prior art date
Application number
PCT/DK2013/050431
Other languages
French (fr)
Inventor
Elise Champion
Gyula Dekany
Nikolay Khanzhin
Pierre CHASSAGNE
Györgyi OSZTROVSZKY
Original Assignee
Glycom A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom A/S filed Critical Glycom A/S
Priority to EP13861993.7A priority Critical patent/EP2931737A4/en
Priority to US14/651,710 priority patent/US20150320780A1/en
Publication of WO2014090261A1 publication Critical patent/WO2014090261A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/12—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a process for producing a mixture containing at least one of 2'-FL (2'-0-fucosyilactose, Fuc(a l-2)Gal(pl-4)Gic) and 3-FL (3-O-fucosyllactose, Gal(pi- 4) [Fuc(a l-3)]Glc), and optionally containing DFL (difucosyi-lactose, Fuc(a l-2)Gai(pl- 4) [Fuc(ei l-3)]Glc) ,
  • HMOs Human milk oligosaccharides
  • DFL, 2'-FL and 3-FL are considered to be among the more important HMOs because of their nutritional value (see VVO 2012/158517) . Because of the growing commercial interest in nutritional formulations and supplements containing HMOs, there has been a need for a low cost method of making such HMOs and mixtures thereof. DFL was first isolated from mother's milk and its structure was elucidated with standard chemical methods including acid hydrolysis (Kuhn et al. Liebigs Ann. Chem. 611, 249 ( 1958)) ,
  • a method for partially hydrolysing DFL to give at least one of 2'-FL or 3-FL The invention thus provides a method for making a mixture containing at least one of 2'-FL and 3-FL, and optionally containing DFL, by subjecting DFL to partial hydrolysis,
  • fucose (6-deoxy-L-gaiactose) and possibly lactose are produced as by-products
  • a partial hydrolysis of DFL mediated by a fucosidase provides a method for making one of 2'-FL or 3- FL, together with fucose.
  • a partial hydrolysis of DFL mediated by an acid provides a method for making 2'-FL and/or 3-FL, together with fucose.
  • Fig . 2 shows the hydrolysis of DFL in 2'-FL and fucose using the a- l,3/4-fucosidase
  • the first aspect of the invention is a method of making a mixture containing 2'-FL or 3-FL by subjecting DFL to partial hydrolysis mediated by a fucosidase.
  • fucose is produced as a significant by-product and lactose can also be produced in small, not significant amounts, but preferably no lactose is produced.
  • a fucosidase that can release one of the fucosyl residues from DFL is preferably used for this partial hydrolysis.
  • the partial hydrolysis of DFL with the fucosidase produces a selective hydrolysis.
  • a mixture of DFL and at least one of 2'-FL and 3-FL can be obtained . This is particularly so when the enzyme treatment is carried out for a shorter time so as not to lead to total consumption of DFL.
  • One group of suitable fucosidases for this partial enzymatic hydrolysis belongs to the glycoside hydrolase family GH95 and are characterized by, and assigned to EC number 3.2. 1.63.
  • 1,2-a-L-fucosidases cannot cleave the 3-O-fucosyi residue of DFL. As a result, they produce a mixture containing substantially no 2'-FL, i.e., no more than 2 w/w%, preferably no more than 1 w/w%, more preferably no more than 0.5 w/w% of 2'-FL, relative to 3-FL.
  • 1,2-a-L-fucosidases have only been known to hydrolyse a 2-0- fucosyl residue from compounds having this fucosyl residue on a terminal galactose residue and not having another fucosyl residue on an adjacent sugar residue.
  • the 1,2-a- L-fucosidase used in this method is one of those disclosed by the following references ;
  • fucosidases for this partial enzymatic hydrolysis belongs to the glycoside hydrolase family GH29 and are characterized by, and assigned to EC number 3,2, 1 , 111 , These 1,3/4-a-L-fucosidases cannot cleave the 2-O-fucosyi residue of DFL, As a result, they produce a mixture containing substantially no 3-FL, i.e.
  • the 1,3/4-a-L-fucosidase used in this method is one of those disclosed by the following references :
  • the fucosidase is denatured and centrifuged. The resulting solution, which contains fucose, is evaporated under reduced pressure. After lyophilisation, the dry residue is dissolved in water, and the mixture of 2'-FL or 3-FL with fucose and optionally with DFL is purified by biogel chromatography with water or by reverse phase chromatography. From the purified fractions, the mixture of 2'-FL or 3-FL with fucose and optionally with DFL can be isolated in solid form by crystallization, iyophilisation, precipitation or spray-drying, or in syrupy form. The above disclosed purification/separation method is suitable to separate 2'-FL or 3-FL from the mixture and to provide them in pure form.
  • the partial hydrolysis of this invention can also be carried out by subjecting DFL to partial acid hydrolysis. This involves gently treating DFL with an acid .
  • the acid can be an organic or inorganic acid, preferably that having pK 3 less than 3-4.
  • Preferred organic acids are formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, oxalic acid, citric acid or sulfonic acids (like benzenesulfonic acid, p-toiuenesulfonic acid, methanesulfonic acid, sulfonate type ion exchange resins), and preferred inorganic acids include mineral acids such as sulfuric acid, nitric acid, hydrochloric acid, perchloric acid, chloric acid, hydrobromic acid or hydroiodic acid .
  • the fucosyi residues of certain amounts of DFL are cleaved.
  • a mixture of unhydrolysed DFL and partially hydroiysed DFL in the form of 2'-FL and optionally 3-FL in various proportions can be obtained .
  • the partial acid hydrolysis always provides more 2'-FL than 3-FL, thereby hydroiysing DFL in a selective manner.
  • the resulting mixture also contains a significant amount of fucose and some lactose.
  • the partial acid hydrolysis of DFL produces a 2'-FL/3-FL ratio of more than 10,
  • DFL is preferably treated with an organic acid, such as a carboxyiic acid, e.g . formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, oxalic acid or citric acid, for 2 or more hours but not more than 24 hours.
  • the hydrolysis is carried out at room temperature when the carboxyiic acid is substituted with a halogen atom, or at more than 50 °C, preferably at about 60-80 °C, when the carboxyiic acid is unsubstituted .
  • fucose is produced as a significant by-product and lactose can also be produced in small amounts, but preferably no significant amount of lactose is produced.
  • the acid in the reaction mixture, containing the DFL, 2'-FL and optionally 3-FL can subsequently be neutralized in a conventional manner by the addition of an equivalent amount of a base, and the resulting salt can be removed by biogel filtration.
  • a heterogeneous cationic ion exchange resin can be removed by simple filtration.
  • the DFL, 2'-FL and optionally 3-FL can be separated in a conventional manner from the fucose and lactose by-products and then isolated in solid form by crystallization,
  • the partial hydrolysis of DFL is carried out with an acid so as to achieve a mixture with a DFL,/2'-FL ratio of from 1:3 to 1:8, preferably from 1:4 to 1:7, more preferably 1:5 to 1:6, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1:5.65, or a DFL/3-FL ratio of from 1:1 to 1:3, preferably from 1:1.5 to 1:2.5, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1:2, or a 3-FL/2'-FL ratio of from 1: 1 to 1:5, preferably from 1:2 to 1:4, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1:2.8.
  • the partial hydrolysis of DFL is carried out with an acid so as to achieve a mixture with a DFL/2'-FL/3-FL ratio resembling that found in human mother's milk, that is a ratio of aboutl:5.65:2.
  • the partial hydrolysis of DFL is carried out with a fucosidase so as to achieve a mixture with a DFL/2'-FL ratio of from 1:3 to 1:8, preferably from 1:4 to 1:7, more preferably 1:5 to 1:6, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1: 5.65, or a DFL/3-FL ratio of from 1:1 to 1:3, preferably from 1:1.5 to 1:2,5, particularly a ratio resembling that found in human mother's milk, that is a ratio of of about 1:2.
  • the method of this invention can readily provide the mixture consisting essentially of DFL, fucose and at least one of 2'-FL and 3-FL and preferably consisting essentially of DFL, fucose, 2'-FL and 3-FL.
  • the DFL/2'-FL/3-FL ratio in these mixtures resembles that found in human mother's milk, that is a ratio of about 1:5,65:2.
  • Both solid and liquid forms of the DFL/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of the present invention can be readily provided with a very high purity suitable for infant nutritional use, e.g. in infant formulas, infant cereals and clinical infant nutritional products.
  • the solid and liquid forms of such mixtures are also suitable for general nutritional use for toddlers, children, adults and the elderly.
  • the solid and liquid forms of such mixtures can also be used as food additives, dietary supplements, components of alcoholic and non-alcoholic beverages such as soft drinks, fruit juices, bottled water, wine and beer.
  • the solid and liquid forms of such mixtures can also be used as therapeutic agents in broad therapeutic application areas, such as to prevent bacterial and viral infections, to avoid diarrhoea and to enhance immune system and brain development.
  • the solid and liquid forms of such mixtures can also be used in veterinary applications, such as to fight against infectious diseases of domesticated animals.
  • the solid and liquid forms of the DFL/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of this invention are also suitable for pharmaceutical and/or therapeutic use,
  • the solid and liquid forms of such mixtures by themselves or in combination with other A/-acety!iactosamine and/or lacto-N-biose and/or fucose and/or sialic acid containing human milk oligosaccharides, are particularly effective in the maturation of the immune system of neonatal infants and have preventive effect against secondary infections following viral infections such as influenza .
  • the solid and liquid forms of such mixtures can be used as prebiotics to enhance the beneficial effects and efficiency of probiotics, such as Lactobacillus and Bifidobacterium species, in promoting the development of an early bifidogenic intestinal microbiota in infants, in reducing their risk of developing allergies and/or asthma and in preventing and treating pathogenic infections, such as diarrhoea, in infants.
  • probiotics such as Lactobacillus and Bifidobacterium species
  • solid and liquid forms of the DFL,/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of this invention can also be used as active ingredients in pharmaceutical compositions, together with one or more pharmaceutically acceptable carriers. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences.
  • such pharmaceutical compositions also contain one or more conventional additives, adj uvants, excipients and diluents, such as water, gelatine, talc, sugars, starch, gum arabic, vegetable gums, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, lubricants, colorants, fillers and wetting agents.
  • the dosage form for administration of such pharmaceutical compositions can be, for example, conventional tablets, powders, granules, pills, suspensions, emulsions, infusions, capsules, syrups, injections, liquids, elixirs, extracts or tinctures.
  • the solid and liquid forms of such mixtures can also be used for the preparation of such pharmaceutical compositions.
  • the solid and liquid forms of the DFL/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of this invention can further be used in food, drink or feed formulations.
  • the amounts of such mixtures in these formulations can vary depending on whether the formulations are intended for use with normal, healthy infants, children, adults or the elderly or for use with individuals having specialized needs (e.g. suffering from metabolic disorders) .
  • Such nutritional formulations can also contain edible micronutrients, vitamins and minerals.
  • M icronutrients can include, for example, edible oils, fats or fatty acids (such as coconut oil, soy-bean oil, monoglycerides, diglycerides, pa!m o!ein, sunflower oil, fish oil, linoleic acid or linoienic acid), carbohydrates (such as glucose, fructose, sucrose, maltodextrin, starch or hydrolysed cornstarch), and proteins from casein, soy-bea n, whey or skim milk, or hydrolysates of these proteins, but protein from other sources (either intact or hydrolysed) can be used as well,
  • Such nutritional formulations can also contain one or more of the following vitamins ; A, Bl, B2, B5, B6, B12, C, D, E, H, K, folic acid, inositol and nicotinic acid and one or more of the following minerals and trace elements : Ca, P, K, Ma, CI, Mg, Mn, Fe, Cu, Z
  • a preferred nutritional formulation containing a soiid or liquid form of a DFL,/2'-FL/3-FL, DFL/2'-FL or DFL/3-FL mixture of this invention is an infant formula, i.e. , a foodstuff intended for particular nutritional use by infants during their first 4-6 months of life and satisfying by itself the nutritional requirements of infants. It may contain one or more probiotics, i.e. , a foodstuff intended for particular nutritional use by infants during their first 4-6 months of life and satisfying by itself the nutritional requirements of infants. It may contain one or more probiotic
  • Bifidobacterium species prebiotics such as fructooligosaccharides and
  • the infant formula can contain the mixture of this invention in a total amount of 0.1-3, 0 g/100 g formula .
  • Another preferred nutritional formulation is a food supplement containing a soiid or liquid form of a DFL/ ' 2'-FL/3-FL, DFL/2'-FL or DFL/3-FL mixture of this invention .
  • the food supplement can also contain one or more probiotics in an amount sufficient to achieve the desired effect in an individual, preferably in children and adults.
  • the food supplement can also contain vitamins, minerals, trace elements and other micronutrients as well.
  • the food supplement can be, for example, in the form of conventional tablets, capsules, pastilles or a liquid .
  • the supplement can contain conventional additives, such as binders, coatings, emulsifiers, solubilising agents, encapsulating agents, film forming agents, adsorbents, carriers, fillers, dispersing agents, wetting agents, jellifying agents and gel forming agents.
  • An especially preferred nutritional formulation is a digestive health functional food (e.g . in the form of tablets, capsules, powders or the like), used to enhance and preserve digestive health, (Such a nutritional formulation is also commonly called a dietary supplement or nutraceutical.)
  • DFL 10 mM
  • a solution of DFL 10 mM was incubated with the 1,3,/4-a-L-fucosidase Blon instruct2336 from Bifidobacterium iongum subsp. infantis atcc 15697 at 37 °C in an incubation buffer ( 100 mM potassium phosphate, pH 6.5) , Different concentrations of enzyme extracts were used ; 0.2 mg/ml, 2.0 mg/ml and 20 mg/ml as final concentration. Hydrolysis of DFL was followed by HPLC and new products were detected by CAD. As shown on Figure 2 DFL was fully hydroiysed in 2'-FL and fucose after 18 hours. Lactose could be detected only when the enzyme extract was used in a high concentration (20 mg/ml) .
  • Example 3 Selective hydrolysis of DFL with acids DFL (50 mg) was dissolved in water (0.5 ml) and treated with acid under the conditions indicated in the table below. Samples were analysed by HPLC using CAD detection.
  • b includes also Glc and Gal (0.5 %)
  • c includes also Glc and Gal (2 %)

Abstract

A method to form a mixture containing at least one of 2'-FL (2'-O-fucosyllactose, Fuc(a1-2)Gai(β1-4)Glc) and 3-FL (3-O-fucosyllactose, Gal(β1-4)[Fuc(a1-3)]Glc)characterized in that DFL (difucosyl-lactose, Fuc(a1-2)Gal(β1-4)[Fuc(a1-3)]Glc) is subjected to partial hydrolysis, e.g. enzymatic hydrolysis or acid hydrolysis,

Description

Mixture of fucosylate lactoses
FIELD OF THE INVENTION
The present invention relates to a process for producing a mixture containing at least one of 2'-FL (2'-0-fucosyilactose, Fuc(a l-2)Gal(pl-4)Gic) and 3-FL (3-O-fucosyllactose, Gal(pi- 4) [Fuc(a l-3)]Glc), and optionally containing DFL (difucosyi-lactose, Fuc(a l-2)Gai(pl- 4) [Fuc(ei l-3)]Glc) ,
BACKGROUND OF THE INVENTION
Human milk oligosaccharides (HMOs) have become of great interest in the past few years due to their important functions in human development. To date, the structures of at least 115 HMOs have been determined, and considerably more are probably present in human milk, DFL, 2'-FL and 3-FL (Scheme 1) are considered to be among the more important HMOs,
2'-FL
Figure imgf000002_0001
Scheme 1 ,
To date, ways of making large volumes of DFL, 2'-FL and 3-FL have not been available, The isolation of fucosylated oligosaccharides from human milk has been rather difficult, even in milligram quantities, due to the presence of a large number of other similar oligosaccharides in human milk. This problem has not been solved by current biotechnology or synthetic chemistry technology.
DFL, 2'-FL and 3-FL are considered to be among the more important HMOs because of their nutritional value (see VVO 2012/158517) . Because of the growing commercial interest in nutritional formulations and supplements containing HMOs, there has been a need for a low cost method of making such HMOs and mixtures thereof. DFL was first isolated from mother's milk and its structure was elucidated with standard chemical methods including acid hydrolysis (Kuhn et al. Liebigs Ann. Chem. 611, 249 ( 1958)) ,
SUMMARY OF THE INVENTION In accordance with this invention, a method is provided for partially hydrolysing DFL to give at least one of 2'-FL or 3-FL, The invention thus provides a method for making a mixture containing at least one of 2'-FL and 3-FL, and optionally containing DFL, by subjecting DFL to partial hydrolysis, In carrying out this method, fucose (6-deoxy-L-gaiactose) and possibly lactose are produced as by-products, According to one aspect of the method, a partial hydrolysis of DFL mediated by a fucosidase provides a method for making one of 2'-FL or 3- FL, together with fucose. According to another aspect of the method, a partial hydrolysis of DFL mediated by an acid provides a method for making 2'-FL and/or 3-FL, together with fucose.
Also in accordance with this invention are provided : - a mixture consisting essentially of DFL, fucose and at least one of 2'-FL and 3-FL; a nd - a mixture consisting essentially of DFL, 2'-FL, 3-FL and fucose. BRIEF DESCRIPTION OF THE FIGURES
The invention will be described in further detail hereinafter with reference to the
accompanying figures, in which : Fig . l shows the hydrolysis of DFL with the 1,2-a-L-fucosidase from Xanthomonas manihotis ATCC# 49764 (bottom curve: t= 0 h; upper curve : t= 18 h) ; and
Fig . 2 shows the hydrolysis of DFL in 2'-FL and fucose using the a- l,3/4-fucosidase
(Blon .2336) from Bifidobacterium !ongum subsp. infantis atcc 15697 (chromatogram 1 : t= 0 h; chromatogram 2 : t= 18 h, [Enz. extract]= 0.2 mg/ml; chromatogram 3 : t= 18 h, [Enz. extract] = 2.0 mg/ml; chromatogram 4: t= 18 h, [Enz, extract] = 20 mg/ml) . DETAILED DESCRIPTION OF THE INVENTION
By a partial hydrolysis of DFL, initiated by an acid or mediated by a fucosidase, a mixture containing at least one of 2'-FL and 3-FL (or both), and optionally containing DFL, can be obtained , The first aspect of the invention is a method of making a mixture containing 2'-FL or 3-FL by subjecting DFL to partial hydrolysis mediated by a fucosidase. In carrying out this method, fucose is produced as a significant by-product and lactose can also be produced in small, not significant amounts, but preferably no lactose is produced.
For this partial hydrolysis, a fucosidase that can release one of the fucosyl residues from DFL is preferably used . In this regard, the partial hydrolysis of DFL with the fucosidase produces a selective hydrolysis. Depending on the activity of the fucosidase and/or its concentration and/or the Iength of time of the reaction, a mixture of DFL and at least one of 2'-FL and 3-FL can be obtained . This is particularly so when the enzyme treatment is carried out for a shorter time so as not to lead to total consumption of DFL. One group of suitable fucosidases for this partial enzymatic hydrolysis belongs to the glycoside hydrolase family GH95 and are characterized by, and assigned to EC number 3.2. 1.63. These 1,2-a-L-fucosidases cannot cleave the 3-O-fucosyi residue of DFL. As a result, they produce a mixture containing substantially no 2'-FL, i.e., no more than 2 w/w%, preferably no more than 1 w/w%, more preferably no more than 0.5 w/w% of 2'-FL, relative to 3-FL. (Previously, known 1,2-a-L-fucosidases have only been known to hydrolyse a 2-0- fucosyl residue from compounds having this fucosyl residue on a terminal galactose residue and not having another fucosyl residue on an adjacent sugar residue.) Preferably, the 1,2-a- L-fucosidase used in this method is one of those disclosed by the following references ;
Figure imgf000004_0001
Figure imgf000005_0002
Another group of suitable fucosidases for this partial enzymatic hydrolysis belongs to the glycoside hydrolase family GH29 and are characterized by, and assigned to EC number 3,2, 1 , 111 , These 1,3/4-a-L-fucosidases cannot cleave the 2-O-fucosyi residue of DFL, As a result, they produce a mixture containing substantially no 3-FL, i.e. , no more than 2 w/w%, preferably no more than 1 w/w%, more preferably no more than 0.5 w/w% 3-FL relative to 2'-FL, (Previously, known 1,3/4-a-L-fucosidases have only been known to hydrolyse a 3/4-0- fucosyl residue from compounds having this fucosyi residue on an intermediate N-acetyl- glucosamine or on a glucose residue and not having another fucosyi residue on an adjacent sugar residue.) Preferably, the 1,3/4-a-L-fucosidase used in this method is one of those disclosed by the following references :
Figure imgf000005_0001
After the partial enzymatic hydrolysis, the fucosidase is denatured and centrifuged. The resulting solution, which contains fucose, is evaporated under reduced pressure. After lyophilisation, the dry residue is dissolved in water, and the mixture of 2'-FL or 3-FL with fucose and optionally with DFL is purified by biogel chromatography with water or by reverse phase chromatography. From the purified fractions, the mixture of 2'-FL or 3-FL with fucose and optionally with DFL can be isolated in solid form by crystallization, iyophilisation, precipitation or spray-drying, or in syrupy form. The above disclosed purification/separation method is suitable to separate 2'-FL or 3-FL from the mixture and to provide them in pure form.
The partial hydrolysis of this invention can also be carried out by subjecting DFL to partial acid hydrolysis. This involves gently treating DFL with an acid . The acid can be an organic or inorganic acid, preferably that having pK3 less than 3-4. Preferred organic acids are formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, oxalic acid, citric acid or sulfonic acids (like benzenesulfonic acid, p-toiuenesulfonic acid, methanesulfonic acid, sulfonate type ion exchange resins), and preferred inorganic acids include mineral acids such as sulfuric acid, nitric acid, hydrochloric acid, perchloric acid, chloric acid, hydrobromic acid or hydroiodic acid . In the partial acid hydrolysis of this invention, one or both of the fucosyi residues of certain amounts of DFL are cleaved. Depending on the pH, the temperature and the length of time of the hydrolysis, a mixture of unhydrolysed DFL and partially hydroiysed DFL in the form of 2'-FL and optionally 3-FL in various proportions can be obtained . More precisely, the partial acid hydrolysis always provides more 2'-FL than 3-FL, thereby hydroiysing DFL in a selective manner. After the partial acid hydrolysis, the resulting mixture also contains a significant amount of fucose and some lactose.
Preferably, the partial acid hydrolysis of DFL produces a 2'-FL/3-FL ratio of more than 10, For this purpose, DFL is preferably treated with an organic acid, such as a carboxyiic acid, e.g . formic acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, oxalic acid or citric acid, for 2 or more hours but not more than 24 hours. Preferably, the hydrolysis is carried out at room temperature when the carboxyiic acid is substituted with a halogen atom, or at more than 50 °C, preferably at about 60-80 °C, when the carboxyiic acid is unsubstituted . Water and mixtures of water and organic protic or aprotic solvents which are stable under acidic conditions and fully or partially miscible with water, such as Ci-C6 alcohols, acetone, THF, dioxane and MeCN, can be used as solvents. In carrying out this partial acid hydrolysis, fucose is produced as a significant by-product and lactose can also be produced in small amounts, but preferably no significant amount of lactose is produced. The acid in the reaction mixture, containing the DFL, 2'-FL and optionally 3-FL can subsequently be neutralized in a conventional manner by the addition of an equivalent amount of a base, and the resulting salt can be removed by biogel filtration. Alternatively, a heterogeneous cationic ion exchange resin can be removed by simple filtration. From the resulting neutralized reaction mixture, the DFL, 2'-FL and optionally 3-FL can be separated in a conventional manner from the fucose and lactose by-products and then isolated in solid form by crystallization,
lyophilisation, precipitation or spray-drying or in syrupy form,
In another preferred embodiment, the partial hydrolysis of DFL is carried out with an acid so as to achieve a mixture with a DFL,/2'-FL ratio of from 1:3 to 1:8, preferably from 1:4 to 1:7, more preferably 1:5 to 1:6, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1:5.65, or a DFL/3-FL ratio of from 1:1 to 1:3, preferably from 1:1.5 to 1:2.5, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1:2, or a 3-FL/2'-FL ratio of from 1: 1 to 1:5, preferably from 1:2 to 1:4, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1:2.8. I a most preferred embodiment the partial hydrolysis of DFL is carried out with an acid so as to achieve a mixture with a DFL/2'-FL/3-FL ratio resembling that found in human mother's milk, that is a ratio of aboutl:5.65:2.
Yet in another preferred embodiment, the partial hydrolysis of DFL is carried out with a fucosidase so as to achieve a mixture with a DFL/2'-FL ratio of from 1:3 to 1:8, preferably from 1:4 to 1:7, more preferably 1:5 to 1:6, particularly a ratio resembling that found in human mother's milk, that is a ratio of about 1: 5.65, or a DFL/3-FL ratio of from 1:1 to 1:3, preferably from 1:1.5 to 1:2,5, particularly a ratio resembling that found in human mother's milk, that is a ratio of of about 1:2.
The method of this invention can readily provide the mixture consisting essentially of DFL, fucose and at least one of 2'-FL and 3-FL and preferably consisting essentially of DFL, fucose, 2'-FL and 3-FL. Preferably, the DFL/2'-FL/3-FL ratio in these mixtures resembles that found in human mother's milk, that is a ratio of about 1:5,65:2.
Both solid and liquid forms of the DFL/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of the present invention can be readily provided with a very high purity suitable for infant nutritional use, e.g. in infant formulas, infant cereals and clinical infant nutritional products. As a result, the solid and liquid forms of such mixtures are also suitable for general nutritional use for toddlers, children, adults and the elderly. The solid and liquid forms of such mixtures can also be used as food additives, dietary supplements, components of alcoholic and non-alcoholic beverages such as soft drinks, fruit juices, bottled water, wine and beer. The solid and liquid forms of such mixtures can also be used as therapeutic agents in broad therapeutic application areas, such as to prevent bacterial and viral infections, to avoid diarrhoea and to enhance immune system and brain development. The solid and liquid forms of such mixtures can also be used in veterinary applications, such as to fight against infectious diseases of domesticated animals. The solid and liquid forms of the DFL/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of this invention are also suitable for pharmaceutical and/or therapeutic use, The solid and liquid forms of such mixtures, by themselves or in combination with other A/-acety!iactosamine and/or lacto-N-biose and/or fucose and/or sialic acid containing human milk oligosaccharides, are particularly effective in the maturation of the immune system of neonatal infants and have preventive effect against secondary infections following viral infections such as influenza . The solid and liquid forms of such mixtures can be used as prebiotics to enhance the beneficial effects and efficiency of probiotics, such as Lactobacillus and Bifidobacterium species, in promoting the development of an early bifidogenic intestinal microbiota in infants, in reducing their risk of developing allergies and/or asthma and in preventing and treating pathogenic infections, such as diarrhoea, in infants.
The solid and liquid forms of the DFL,/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of this invention can also be used as active ingredients in pharmaceutical compositions, together with one or more pharmaceutically acceptable carriers. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences. Preferably, such pharmaceutical compositions also contain one or more conventional additives, adj uvants, excipients and diluents, such as water, gelatine, talc, sugars, starch, gum arabic, vegetable gums, vegetable oils, polyalkylene glycols, flavouring agents, preservatives, stabilizers, emulsifying agents, lubricants, colorants, fillers and wetting agents. The dosage form for administration of such pharmaceutical compositions can be, for example, conventional tablets, powders, granules, pills, suspensions, emulsions, infusions, capsules, syrups, injections, liquids, elixirs, extracts or tinctures. The solid and liquid forms of such mixtures can also be used for the preparation of such pharmaceutical compositions.
The solid and liquid forms of the DFL/2'-FL/3-FL, DFL/2'-FL and DFL/3-FL mixtures of this invention can further be used in food, drink or feed formulations. The amounts of such mixtures in these formulations can vary depending on whether the formulations are intended for use with normal, healthy infants, children, adults or the elderly or for use with individuals having specialized needs (e.g. suffering from metabolic disorders) . Such nutritional formulations can also contain edible micronutrients, vitamins and minerals. M icronutrients can include, for example, edible oils, fats or fatty acids (such as coconut oil, soy-bean oil, monoglycerides, diglycerides, pa!m o!ein, sunflower oil, fish oil, linoleic acid or linoienic acid), carbohydrates (such as glucose, fructose, sucrose, maltodextrin, starch or hydrolysed cornstarch), and proteins from casein, soy-bea n, whey or skim milk, or hydrolysates of these proteins, but protein from other sources (either intact or hydrolysed) can be used as well, Such nutritional formulations can also contain one or more of the following vitamins ; A, Bl, B2, B5, B6, B12, C, D, E, H, K, folic acid, inositol and nicotinic acid and one or more of the following minerals and trace elements : Ca, P, K, Ma, CI, Mg, Mn, Fe, Cu, Zn, Se, Cr or I. The soiid and liquid forms of such mixtures can also be used for the prepa ration of such nutritional formulations
A preferred nutritional formulation containing a soiid or liquid form of a DFL,/2'-FL/3-FL, DFL/2'-FL or DFL/3-FL mixture of this invention is an infant formula, i.e. , a foodstuff intended for particular nutritional use by infants during their first 4-6 months of life and satisfying by itself the nutritional requirements of infants. It may contain one or more probiotic
Bifidobacterium species, prebiotics such as fructooligosaccharides and
galactooligosaccharides, proteins from casein, soy-bean, whey or skim milk, carbohydrates such as lactose, saccharose, maitodextrin, starch or mixtures thereof, lipids (e.g . palm olein, sunflower oil or saffiower oil) and vitamins and minerals essential in a daily diet. The infant formula can contain the mixture of this invention in a total amount of 0.1-3, 0 g/100 g formula .
Another preferred nutritional formulation is a food supplement containing a soiid or liquid form of a DFL/'2'-FL/3-FL, DFL/2'-FL or DFL/3-FL mixture of this invention . The food supplement can also contain one or more probiotics in an amount sufficient to achieve the desired effect in an individual, preferably in children and adults. The food supplement can also contain vitamins, minerals, trace elements and other micronutrients as well. The food supplement can be, for example, in the form of conventional tablets, capsules, pastilles or a liquid . The supplement can contain conventional additives, such as binders, coatings, emulsifiers, solubilising agents, encapsulating agents, film forming agents, adsorbents, carriers, fillers, dispersing agents, wetting agents, jellifying agents and gel forming agents. An especially preferred nutritional formulation is a digestive health functional food (e.g . in the form of tablets, capsules, powders or the like), used to enhance and preserve digestive health, (Such a nutritional formulation is also commonly called a dietary supplement or nutraceutical.)
EXAMPLES
Example 1 - Enzymatic hydrolysis of DFL with 1,2-a-L-fucosidase
A solution of DFL ( 10 mM) was incubated with the 1,2-a-L-fucosidase from Xanthomonas manihotis ATCC# 49764 (500 U/ml) at 37 °C in an incubation buffer (50 mM sodium citrate, pH 6.0) . Hydrolysis of DFL was followed by HPLC and new products were detected by CAD. As shown on Figure 1 DFL was partially hydroiysed in 3-FL and fucose after 18 hours. No lactose could be detected . Example 2 - Enzymatic hydrolysis of DFL with 1,3/4-a-L-fucosidase
A solution of DFL ( 10 mM) was incubated with the 1,3,/4-a-L-fucosidase Blon„2336 from Bifidobacterium iongum subsp. infantis atcc 15697 at 37 °C in an incubation buffer ( 100 mM potassium phosphate, pH 6.5) , Different concentrations of enzyme extracts were used ; 0.2 mg/ml, 2.0 mg/ml and 20 mg/ml as final concentration. Hydrolysis of DFL was followed by HPLC and new products were detected by CAD. As shown on Figure 2 DFL was fully hydroiysed in 2'-FL and fucose after 18 hours. Lactose could be detected only when the enzyme extract was used in a high concentration (20 mg/ml) .
Example 3 - Selective hydrolysis of DFL with acids DFL (50 mg) was dissolved in water (0.5 ml) and treated with acid under the conditions indicated in the table below. Samples were analysed by HPLC using CAD detection.
Figure imgf000010_0001
Figure imgf000011_0002
a no Lac detected
b includes also Glc and Gal (0.5 %)
c includes also Glc and Gal (2 %)
d includes also Glc and Gal (9 %) Example 4 - Selective hydrolysis of DFL with acids
DFL (50 mg) was dissolved in 80 % aq. acetic acid or 50 % aq. TFA solution (250 μΙ) and stirred at the temperature indicated in the table below. Follow up of the reaction was monitored by HPLC (CAD detector) .
Figure imgf000011_0001
Example 5 - Selective hydrolysis of DFL with acids
DFL (50 mg) was dissolved in a buffer solution (250 μΙ) and stirred at the temperature indicated in the table below. Follow up of the reaction was monitored by HPLC (CAD detector) . Buffers were made according to " Electrolyte solutions" Robinson, R. A., and Stokes, R. H . , 2nd ed ., rev. London, Butterworths, 1968, and "Practical chemistry" J . Lambert and T.A. Muir, 3rd . Ed . Heineman, London, 1973.
Figure imgf000012_0001

Claims

1. A method to form a mixture containing at least one of 2'-FL and 3-FL characterized in that DFL (difucosyl-lactose) is subjected to partial hydrolysis,
2. The method according to claim 1, wherein the mixture contains DFL and at least one of 2'-FL and 3-FL.
3. The method according to any one of the claims 1 and 2, which is mediated by a fucosidase.
4. The method according to claim 3, wherein the fucosidase a 1,2-a-L-fucosidase and the mixture contains DFL, 3-FL and substantially no 2'-FL.
5. The method according to claim 3, wherein the fucosidase is a 1,3/4-a-L-fucosidase and the mixture contains DFL, 2'-FL and substantially no 3-FL.
6. The method according to claim 3, wherein all the DFL is converted to one of 2'-FL or 3-FL,
7. The method according to claim 6, wherein all the DFL is converted to 3-FL by
treatment with a 1,2-a-L-fucosidase,
8. The method according to claim 6, wherein all the DFL is converted to 2'-FL by
treatment with a 1,3/4-a-L-fucosidase,
9. The method according to any one of the claims 1 to 8, wherein the mixture also contains fucose.
10. A mixture consisting essentia lly of DFL (difucosyl-lactose), fucose and at least one of 2'-FL and 3-FL.
11. A mixture according to claim 10 as a pharmaceutical agent,
12. Use of a mixture according to claim 10 for the preparation of a pharmaceutical
composition ,
13. Pharmaceutical compositions comprising a mixture according claim 10, and one or more pharmaceutically acceptable carriers,
14. Nutritional formulations comprising a mixture according to claim 10.
15. A nutritional formulation according to claim 14, which is an infant formula .
16, A nutritional formulation according to claim 14, which is a food supplement.
17. A food supplement according to claim 16, which is a digestive health functional food .
18. Use of a mixture according to claim 10 for the preparation of a nutritional formulation.
PCT/DK2013/050431 2012-12-14 2013-12-13 Mixture of fucosylate lactoses WO2014090261A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13861993.7A EP2931737A4 (en) 2012-12-14 2013-12-13 Mixture of fucosylate lactoses
US14/651,710 US20150320780A1 (en) 2012-12-14 2013-12-13 Mixture of fucosylate lactoses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201270787 2012-12-14
DKPA201270787 2012-12-14

Publications (1)

Publication Number Publication Date
WO2014090261A1 true WO2014090261A1 (en) 2014-06-19

Family

ID=50933775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2013/050431 WO2014090261A1 (en) 2012-12-14 2013-12-13 Mixture of fucosylate lactoses

Country Status (3)

Country Link
US (1) US20150320780A1 (en)
EP (1) EP2931737A4 (en)
WO (1) WO2014090261A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032412A1 (en) * 2013-09-06 2015-03-12 Glycom A/S Fermentative production of oligosaccharides
WO2016086947A1 (en) * 2014-12-05 2016-06-09 Glycom A/S Crystalline difucosyllactose
EP3389404B1 (en) 2015-12-15 2019-10-02 Société des Produits Nestlé S.A. Mixture of hmos
EP3569713A1 (en) 2018-05-16 2019-11-20 Jennewein Biotechnologie GmbH Use of glycosidases in the production of oligosaccharides
WO2020106870A3 (en) * 2018-11-21 2020-07-30 Amyris, Inc. Biosynthesis of compounds in yeast
EP3209673B1 (en) 2014-10-24 2020-08-19 Glycom A/S MIXTURES OF HMOs
WO2021094133A3 (en) * 2019-11-13 2021-06-24 Basf Se Enzymatic hydrolysis of 2',3-difucosyllactose

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043494A1 (en) * 1997-03-31 1998-10-08 Abbott Laboratories Nutritional formulations containing oligosaccharides
WO2012112777A2 (en) * 2011-02-16 2012-08-23 Glycosyn LLC Biosynthesis of human milk oligosaccharides in engineered bacteria
WO2012156897A1 (en) * 2011-05-13 2012-11-22 Glycom A/S METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
WO2012156898A1 (en) * 2011-05-13 2012-11-22 Glycom A/S DIVERSIFICATION OF HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19701382A1 (en) * 1997-01-16 1998-07-23 Nutricia Nv Carbohydrate mix
US9902984B2 (en) * 2013-09-06 2018-02-27 Glycom A/S Fermentative production of oligosaccharides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043494A1 (en) * 1997-03-31 1998-10-08 Abbott Laboratories Nutritional formulations containing oligosaccharides
WO2012112777A2 (en) * 2011-02-16 2012-08-23 Glycosyn LLC Biosynthesis of human milk oligosaccharides in engineered bacteria
WO2012156897A1 (en) * 2011-05-13 2012-11-22 Glycom A/S METHOD FOR GENERATING HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
WO2012156898A1 (en) * 2011-05-13 2012-11-22 Glycom A/S DIVERSIFICATION OF HUMAN MILK OLIGOSACCHARIDES (HMOs) OR PRECURSORS THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ-MAYORALAS, A. ET AL.: "Synthesis of 3- and 2'-fucosyl-lactose and 3,2'-difucosyllactose from partially benzylated lactose derivatives'.", CARBOHYDRATE RESEARCH, vol. 154, no. 1, 15 October 1986 (1986-10-15), pages 93 - 101, XP026618813 *
See also references of EP2931737A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032412A1 (en) * 2013-09-06 2015-03-12 Glycom A/S Fermentative production of oligosaccharides
US9902984B2 (en) 2013-09-06 2018-02-27 Glycom A/S Fermentative production of oligosaccharides
EP3209673B1 (en) 2014-10-24 2020-08-19 Glycom A/S MIXTURES OF HMOs
WO2016086947A1 (en) * 2014-12-05 2016-06-09 Glycom A/S Crystalline difucosyllactose
EP3227309A4 (en) * 2014-12-05 2019-01-16 Glycom A/S Crystalline difucosyllactose
US10500221B2 (en) 2014-12-05 2019-12-10 Glycom A/S Crystalline difucosyllactose
EP3389404B1 (en) 2015-12-15 2019-10-02 Société des Produits Nestlé S.A. Mixture of hmos
US11957148B2 (en) 2015-12-15 2024-04-16 Societe Des Produits Nestle S.A. Mixture of human milk oligosaccharides(HMOs)
EP3569713A1 (en) 2018-05-16 2019-11-20 Jennewein Biotechnologie GmbH Use of glycosidases in the production of oligosaccharides
WO2019219578A1 (en) 2018-05-16 2019-11-21 Jennewein Biotechnologie Gmbh Use of glycosidases in the production of oligosaccharides
WO2020106870A3 (en) * 2018-11-21 2020-07-30 Amyris, Inc. Biosynthesis of compounds in yeast
WO2021094133A3 (en) * 2019-11-13 2021-06-24 Basf Se Enzymatic hydrolysis of 2',3-difucosyllactose

Also Published As

Publication number Publication date
EP2931737A4 (en) 2016-11-16
EP2931737A1 (en) 2015-10-21
US20150320780A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
EP2931737A1 (en) Mixture of fucosylate lactoses
US10499668B2 (en) Nutritional products comprising human milk oligosaccharides and methods for manufacture thereof
RU2607457C2 (en) Milk oligosaccharide-galactooligosaccharide composition for infant formula, containing soluble oligosaccharide fraction present in milk, and having low level of monosaccharides, and process to produce composition
US8795651B2 (en) Method of fortifying a foodstuff with sialic acid producing bacteria
KR101449976B1 (en) Composition for oral administration
EP3981255A1 (en) Nutritional composition
US20170080002A1 (en) Methods for providing sialylated oligosaccharides
JP5465834B2 (en) Liver function protectant
JP2023073244A (en) Intestinal environment improvement composition and method for manufacturing the same
JP6954676B2 (en) Phenylalanine-free protein for PKU treatment
JP2014125431A (en) Isoflavone conversion promotion composition
US20230313250A1 (en) Galacto-oligosaccharide having a terminal mannose residue, its preparation and application
JP4050799B2 (en) Tight junction formation accelerator
Vera et al. Galacto-oligosaccharides
Vera et al. Galacto-oligosaccharides 41
JP2009161443A (en) Oral administration composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13861993

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2013861993

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14651710

Country of ref document: US